Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1719898

registered interest
date	21/05/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Pharmacy
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government what the uptake has been of the NHS Pharmacy First programme launched in January.
tabling member printed	Baroness Redfern
uin	HL4821
answer	answer is ministerial correction date of answer 23/05/2024 answer text <p>Pharmacy First was launched on 31 January 2024, with 98% of pharmacies having signed up. From the end of May 2024, the NHS Business Service Authority will commence publishing monthly data on the number of clinical consultations claimed for by pharmacy contractors under Pharmacy First.</p> answering member printed Lord Markham question first answered 23/05/2024 14:21:52 answering member 4948 label Biography information for Lord Markham
tabling member	4551 label Biography information for Baroness Redfern

1719918

registered interest
date	21/05/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Long Covid
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government what estimate they have made of the number of people in the UK still suffering the effects of Long Covid.
tabling member printed	Lord Weir of Ballyholme
uin	HL4840
answer	answer is ministerial correction date of answer 23/05/2024 answer text <p>The most recent data from the Winter Covid-19 Infection Study, a joint study carried out by the Office for National Statistics and the UK Health Security Agency, shows that, for the period 6 February 2024 to 7 March 2024, an estimated 2 million people, or 3.3% of the population, in private households in England and Scotland, reported experiencing long COVID symptoms more than four weeks after a COVID-19 infection. Of these, an estimated 1.5 million people reported that day-to-day activity had been limited, of which an estimated 381,000 reported that day-to-day activity had been limited a lot.</p><p>Where data was available to calculate the exact duration of long COVID, this showed that an estimated 164,000 people first had, or suspected they had, COVID-19 less than 12 weeks previously, 1.1 million people had symptoms for 12 or more weeks, 930,000 people for at least a year and 670,000 for at least two years. We do not know the exact duration for an estimated 680,980. These results are based on questionnaire responses from 107,852 participants, where weighted percentages from the questionnaire have been applied to the population total in England and Scotland.</p> answering member printed Lord Markham question first answered 23/05/2024 13:54:32 answering member 4948 label Biography information for Lord Markham
tabling member	4970 label Biography information for Lord Weir of Ballyholme

1718946

registered interest
date	16/05/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Abortion: Telemedicine
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government, further to the Written Answer by Lord Markham on 15 May (HL4224), how they reconcile the answer with that given by the Parliamentary Under Secretary of State for Health and Social Care on 23 November 2023 (HC527), which precluded the ability of a medical practitioner to form a "good faith" opinion through a telemedicine consultation alone that the patient's gestation was below 10 weeks, and therefore to dispense early medical abortion pills for use by the patient at home.
tabling member printed	Lord Jackson of Peterborough
uin	HL4727
answer	answer is ministerial correction date of answer 23/05/2024 answer text <p>The response of 23 November 2023 does not preclude the ability of a medical practitioner to form a good faith opinion, through a telemedicine consultation alone, that the patient's gestation was below 10 weeks. This opinion can be formed either during a teleconsultation, or an in-person appointment.</p><p>Pregnancy duration can be assessed from the first day of the last menstrual period (LMP). Advice from the Royal College of Obstetricians and Gynaecologists is clear that most women can determine the duration of their pregnancy with reasonable accuracy by LMP alone.</p><p>However, if there is any uncertainty about the gestation of the pregnancy, the medical practitioner would ask the woman to attend an in-person appointment to enable them to form an opinion that the pregnancy will not have exceeded 10 weeks at the time the first abortion pill is taken. If she does not attend in-person when requested, the terminating practitioner would not be able to form an opinion in good faith that the pregnancy is below 10 weeks gestation, and therefore would not be able to prescribe abortion pills for home use.</p> answering member printed Lord Markham question first answered 23/05/2024 12:21:34 answering member 4948 label Biography information for Lord Markham
tabling member	1551 label Biography information for Lord Jackson of Peterborough

1718587

registered interest
date	15/05/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Antimicrobials: Sanitation
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government, further to their policy paper Confronting antimicrobial resistance 2024 to 2029, published on 8 May, how the importance placed on water, sanitation and hygiene (WASH) in that paper will be implemented; and whether there will be increased finance for WASH.
tabling member printed	Baroness Hodgson of Abinger
uin	HL4688
answer	answer is ministerial correction date of answer 23/05/2024 answer text <p>Proactive infection prevention and control, in terms of patient safety and antimicrobial resistance (AMR) within the public health system, is a core element of the national action plan.</p><p>Nationally, the UK Health Security Agency (UKHSA) works with partners to provide the evidence base and technical expertise to support best practice in infection prevention and control (IPC) in health and care and other settings, such as schools and prisons. A dedicated research facility at Porton Down also supports studies on the effectiveness of IPC procedures and the role of the built environment in AMR transmission.</p><p>Internationally, AMR activities are supported through a variety of global health initiatives. The World Health Organization (WHO) Collaborating Centre on AMR and Healthcare Associated Infections, which is housed by UKHSA, also provides support for training on AMR diagnostics and surveillance. School aged children can also learn about microbes, IPC, antibiotics and vaccination from free resources via the e-Bug programme.</p><p>The Government continues to finance WASH and global WASH leadership. levels of finance in 2025 and beyond will be confirmed by a Government-wide spending review.</p> answering member printed Lord Markham question first answered 23/05/2024 10:26:48 answering member 4948 label Biography information for Lord Markham
tabling member	4301 label Biography information for Baroness Hodgson of Abinger

1718595

registered interest
date	15/05/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Leukaemia: Mortality Rates
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government what steps they are taking to improve acute myeloid leukaemia survival rates.
tabling member printed	Baroness Merron
uin	HL4696
answer	answer is ministerial correction date of answer 23/05/2024 answer text <p>NHS England has implemented non symptom specific pathways (NSS) for patients who present with non-specific symptoms or combinations thereof that can indicate several different cancers. This includes leukaemia, which can present non-specific symptoms, such as unexpected weight loss and night sweats. As of December 2023, there are 113 NSS pathways already live, an increase from 12 live Rapid Diagnostic Centre pathways in March 2020, with over 5,500 patients seen per month and a total of over 100,000 referrals since May 2020.</p><p>Raising awareness, delivering more research, and improving early diagnosis of cancers, which includes blood related cancers such as leukaemia, are crucial for improving survival rates and are key priorities for the Government.</p><p>NHS England is taking steps to raise awareness of all cancers, including leukaemia, to improve early diagnosis. In January 2024, NHS England relaunched their ‘Help Us Help You’ cancer awareness campaign, designed to increase earlier diagnosis of cancer by encouraging people to come forward with suspected signs of cancers. The campaign aims to reduce barriers to seeking earlier help, as well as to increase body awareness and knowledge of key red flag symptoms. This relaunch follows NHS England’s launch of their original ‘Help Us Help You’ campaigns in April 2020, a major public information campaign to persuade the public to seek urgent care and treatment when they needed it.</p><p>Delivering more research is key to understanding the causes of cancers and increasing survival rates of all cancers, including leukaemia, further. That is why investment in research and innovation is a priority for the Government. Our world-leading scientists and clinicians are driving the discovery, development, and testing of new treatments. The Department invested almost £122 million into cancer research in 2022/23 via the National Institute for Health and Care Research. In addition, alongside Cancer Research UK, health departments across the United Kingdom are jointly funding a network of Experimental Cancer Medicine Centres (ECMCs), collectively investing more than £35 million between 2017 and 2022. The network of 17 adult and 12 paediatric ECMCs enhances the existing bench-to-bedside pathway by supporting the most promising innovations from the academic and industry sectors into the cancer medicines of tomorrow.</p><p>More broadly, the National Health Service is working towards its Long Term Plan ambition of diagnosing 75% of stageable cancers at stage 1 and 2 by 2028. Achieving this will mean that an additional 55,000 people each year will survive their cancer for at least five years after diagnosis. To support early diagnosis, the Government has invested £2.3 billion into community diagnostic centres across England which are speeding up diagnosis for cancer, with checks and scans being delivered at 160 sites across England. Cancer is also one of six major conditions included in our upcoming Major Conditions Strategy.</p><p>With progress made on reducing waiting times, cancer is being diagnosed at an earlier stage more often, with survival rates improving across almost all types of cancer.</p> answering member printed Lord Markham grouped question UIN HL4697 HL4698 question first answered 23/05/2024 10:26:18 answering member 4948 label Biography information for Lord Markham
tabling member	347 label Biography information for Baroness Merron

1718596

registered interest
date	15/05/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Leukaemia: Diagnosis
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government what action they are taking to reduce the rates of emergency diagnosis of leukaemia.
tabling member printed	Baroness Merron
uin	HL4697
answer	answer is ministerial correction date of answer 23/05/2024 answer text <p>NHS England has implemented non symptom specific pathways (NSS) for patients who present with non-specific symptoms or combinations thereof that can indicate several different cancers. This includes leukaemia, which can present non-specific symptoms, such as unexpected weight loss and night sweats. As of December 2023, there are 113 NSS pathways already live, an increase from 12 live Rapid Diagnostic Centre pathways in March 2020, with over 5,500 patients seen per month and a total of over 100,000 referrals since May 2020.</p><p>Raising awareness, delivering more research, and improving early diagnosis of cancers, which includes blood related cancers such as leukaemia, are crucial for improving survival rates and are key priorities for the Government.</p><p>NHS England is taking steps to raise awareness of all cancers, including leukaemia, to improve early diagnosis. In January 2024, NHS England relaunched their ‘Help Us Help You’ cancer awareness campaign, designed to increase earlier diagnosis of cancer by encouraging people to come forward with suspected signs of cancers. The campaign aims to reduce barriers to seeking earlier help, as well as to increase body awareness and knowledge of key red flag symptoms. This relaunch follows NHS England’s launch of their original ‘Help Us Help You’ campaigns in April 2020, a major public information campaign to persuade the public to seek urgent care and treatment when they needed it.</p><p>Delivering more research is key to understanding the causes of cancers and increasing survival rates of all cancers, including leukaemia, further. That is why investment in research and innovation is a priority for the Government. Our world-leading scientists and clinicians are driving the discovery, development, and testing of new treatments. The Department invested almost £122 million into cancer research in 2022/23 via the National Institute for Health and Care Research. In addition, alongside Cancer Research UK, health departments across the United Kingdom are jointly funding a network of Experimental Cancer Medicine Centres (ECMCs), collectively investing more than £35 million between 2017 and 2022. The network of 17 adult and 12 paediatric ECMCs enhances the existing bench-to-bedside pathway by supporting the most promising innovations from the academic and industry sectors into the cancer medicines of tomorrow.</p><p>More broadly, the National Health Service is working towards its Long Term Plan ambition of diagnosing 75% of stageable cancers at stage 1 and 2 by 2028. Achieving this will mean that an additional 55,000 people each year will survive their cancer for at least five years after diagnosis. To support early diagnosis, the Government has invested £2.3 billion into community diagnostic centres across England which are speeding up diagnosis for cancer, with checks and scans being delivered at 160 sites across England. Cancer is also one of six major conditions included in our upcoming Major Conditions Strategy.</p><p>With progress made on reducing waiting times, cancer is being diagnosed at an earlier stage more often, with survival rates improving across almost all types of cancer.</p> answering member printed Lord Markham grouped question UIN HL4696 HL4698 question first answered 23/05/2024 10:26:18 answering member 4948 label Biography information for Lord Markham
tabling member	347 label Biography information for Baroness Merron

1718597

registered interest
date	15/05/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Leukaemia: Health Services
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government what plans they have for developing a best practice timed pathway for leukaemia.
tabling member printed	Baroness Merron
uin	HL4698
answer	answer is ministerial correction date of answer 23/05/2024 answer text <p>NHS England has implemented non symptom specific pathways (NSS) for patients who present with non-specific symptoms or combinations thereof that can indicate several different cancers. This includes leukaemia, which can present non-specific symptoms, such as unexpected weight loss and night sweats. As of December 2023, there are 113 NSS pathways already live, an increase from 12 live Rapid Diagnostic Centre pathways in March 2020, with over 5,500 patients seen per month and a total of over 100,000 referrals since May 2020.</p><p>Raising awareness, delivering more research, and improving early diagnosis of cancers, which includes blood related cancers such as leukaemia, are crucial for improving survival rates and are key priorities for the Government.</p><p>NHS England is taking steps to raise awareness of all cancers, including leukaemia, to improve early diagnosis. In January 2024, NHS England relaunched their ‘Help Us Help You’ cancer awareness campaign, designed to increase earlier diagnosis of cancer by encouraging people to come forward with suspected signs of cancers. The campaign aims to reduce barriers to seeking earlier help, as well as to increase body awareness and knowledge of key red flag symptoms. This relaunch follows NHS England’s launch of their original ‘Help Us Help You’ campaigns in April 2020, a major public information campaign to persuade the public to seek urgent care and treatment when they needed it.</p><p>Delivering more research is key to understanding the causes of cancers and increasing survival rates of all cancers, including leukaemia, further. That is why investment in research and innovation is a priority for the Government. Our world-leading scientists and clinicians are driving the discovery, development, and testing of new treatments. The Department invested almost £122 million into cancer research in 2022/23 via the National Institute for Health and Care Research. In addition, alongside Cancer Research UK, health departments across the United Kingdom are jointly funding a network of Experimental Cancer Medicine Centres (ECMCs), collectively investing more than £35 million between 2017 and 2022. The network of 17 adult and 12 paediatric ECMCs enhances the existing bench-to-bedside pathway by supporting the most promising innovations from the academic and industry sectors into the cancer medicines of tomorrow.</p><p>More broadly, the National Health Service is working towards its Long Term Plan ambition of diagnosing 75% of stageable cancers at stage 1 and 2 by 2028. Achieving this will mean that an additional 55,000 people each year will survive their cancer for at least five years after diagnosis. To support early diagnosis, the Government has invested £2.3 billion into community diagnostic centres across England which are speeding up diagnosis for cancer, with checks and scans being delivered at 160 sites across England. Cancer is also one of six major conditions included in our upcoming Major Conditions Strategy.</p><p>With progress made on reducing waiting times, cancer is being diagnosed at an earlier stage more often, with survival rates improving across almost all types of cancer.</p> answering member printed Lord Markham grouped question UIN HL4696 HL4697 question first answered 23/05/2024 10:26:18 answering member 4948 label Biography information for Lord Markham
tabling member	347 label Biography information for Baroness Merron

1718598

registered interest
date	15/05/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Leukaemia: Health Services
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government what cancer waiting times data are being collected regarding leukaemia and its sub-types; and how these data are being published.
tabling member printed	Baroness Merron
uin	HL4699
answer	answer is ministerial correction date of answer 23/05/2024 answer text <p>For the Faster Diagnostic Standard (FDS), data regarding leukaemia and its sub-types is collected using the following two categories: suspected acute leukaemia; and suspected haematological malignancies, excluding acute leukaemia. The latter category includes non-acute leukaemia when there is a suspicion. These statistics are published monthly and are available on the NHS Cancer Waiting Times website, in an online only format. Performance against the FDS for suspected acute leukaemia in March 2024 was at 74.1%. Performance against the FDS for suspected haematological malignancies, excluding acute leukaemia, in March 2024 was at 56.8%.</p><p>For the 31- and 62-day referral to treatment combined standards, data is collected at an International Classification of Diseases 10 (ICD-10) level, and NHS England publishes data as an aggregation of these reports, to manage the risk of disclosure. Data regarding leukaemia and its sub-types is reported under cancer type ‘Haematological – Other (a)’. These are ICD-10 codes that are haematological, excluding lymphoma, and this aggregation includes ICD-10 codes C91.0 to C96.9, which includes all leukaemia codes. Further information on the ICD-10 classification is available on the NHS England website, in an online only format.</p><p>According to NHS England, the 31-day referral to treatment performance for acute leukaemia, testicular, and children’s cancer is no longer published as a separate category, due to the low numbers of patients seen with these cancers. These patients continue to be included within the numerator and denominator of the 31-day and 62-day all cancer National Statistics, published by NHS England.</p> answering member printed Lord Markham grouped question UIN HL4700 question first answered 23/05/2024 12:08:13 answering member 4948 label Biography information for Lord Markham
tabling member	347 label Biography information for Baroness Merron

1718599

registered interest
date	15/05/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Leukaemia: Diagnosis
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government what proportion of leukaemia patients have received a diagnosis within the 28-day 'faster diagnosis' standard.
tabling member printed	Baroness Merron
uin	HL4700
answer	answer is ministerial correction date of answer 23/05/2024 answer text <p>For the Faster Diagnostic Standard (FDS), data regarding leukaemia and its sub-types is collected using the following two categories: suspected acute leukaemia; and suspected haematological malignancies, excluding acute leukaemia. The latter category includes non-acute leukaemia when there is a suspicion. These statistics are published monthly and are available on the NHS Cancer Waiting Times website, in an online only format. Performance against the FDS for suspected acute leukaemia in March 2024 was at 74.1%. Performance against the FDS for suspected haematological malignancies, excluding acute leukaemia, in March 2024 was at 56.8%.</p><p>For the 31- and 62-day referral to treatment combined standards, data is collected at an International Classification of Diseases 10 (ICD-10) level, and NHS England publishes data as an aggregation of these reports, to manage the risk of disclosure. Data regarding leukaemia and its sub-types is reported under cancer type ‘Haematological – Other (a)’. These are ICD-10 codes that are haematological, excluding lymphoma, and this aggregation includes ICD-10 codes C91.0 to C96.9, which includes all leukaemia codes. Further information on the ICD-10 classification is available on the NHS England website, in an online only format.</p><p>According to NHS England, the 31-day referral to treatment performance for acute leukaemia, testicular, and children’s cancer is no longer published as a separate category, due to the low numbers of patients seen with these cancers. These patients continue to be included within the numerator and denominator of the 31-day and 62-day all cancer National Statistics, published by NHS England.</p> answering member printed Lord Markham grouped question UIN HL4699 question first answered 23/05/2024 12:08:13 answering member 4948 label Biography information for Lord Markham
tabling member	347 label Biography information for Baroness Merron

1718600

registered interest
date	15/05/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Maternity Services
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government whether they will bring forward an overarching national maternity strategy to aid the improvement of maternity services and prevent birth trauma.
tabling member printed	Baroness Northover
uin	HL4701
answer	answer is ministerial correction date of answer 23/05/2024 answer text <p>The Secretary of State for Health and Social Care and NHS England Chief Executive Officer Amanda Pritchard both support the overarching recommendation from the Birth Trauma All-party Parliamentary Group inquiry report, for a comprehensive national strategy to improve maternity services. We will update on next steps in due course.</p><p>We are already making good progress on many of the individual recommendations set out in the inquiry report. This includes new guidance for general practitioners on the postnatal check-up that women should be offered six to eight weeks after giving birth, which is solely focused on the mother. We are also rolling out new physical and mental health services for new mums and mums-to-be so that they are available in all areas of England.</p> answering member printed Lord Markham question first answered 23/05/2024 12:05:02 answering member 4948 label Biography information for Lord Markham
tabling member	2539 label Biography information for Baroness Northover